H.C. Wainwright & Co. Initiates MedinCell’s Coverage with "Buy" Recommendation

MedinCell, a biopharmaceutical company, announced that H.C. Wainwright & Co. has initiated coverage with a "Buy" rating and a price target of €24. This represents an 80% potential increase from the previous day's stock price at market close.

Christophe Douat, CEO of MedinCell, emphasized the significance of this coverage. He stated it underscores the growing interest in MedinCell within the U.S. biopharmaceutical sector and strengthens their objective to enhance visibility among American investors.

This initiation follows significant milestones for MedinCell. These include U.S. FDA approval of UZEDY® and positive Phase 3 results for mdc-TJK. Additionally, a collaboration with AbbVie to co-develop and commercialize multiple therapeutic products was announced.